Altrenogest
This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.
Identification
- Name
- Altrenogest
- Accession Number
- DB11372
- Description
Altrenogest, also known as allyltrenbolone, is a steroidal progestin that is widely used in veterinary medicine to suppress estrus in animals.
- Type
- Small Molecule
- Groups
- Vet approved
- Structure
- Weight
- Average: 310.437
Monoisotopic: 310.193280077 - Chemical Formula
- C21H26O2
- Synonyms
- 17-alpha-Allyl-estratriene-4,9,11,17-beta-ol-3-one
- Allyl trenbolone
- Allyltrenbolone
- Altrenogestum
- External IDs
- A-35957
- DRC 6246
- R 2267
- RU 2267
- RU-2267
Pharmacology
- Indication
- Not Available
- Contraindications & Blackbox Warnings
Learn about our commercial Contraindications & Blackbox Warnings data.
Learn More- Pharmacodynamics
- Not Available
- Mechanism of action
- Not Available
- Absorption
- Not Available
- Volume of distribution
- Not Available
- Protein binding
- Not Available
- Metabolism
- Not Available
- Route of elimination
- Not Available
- Half-life
- Not Available
- Clearance
- Not Available
- Adverse Effects
Learn about our commercial Adverse Effects data.
Learn More- Toxicity
- Not Available
- Affected organisms
- Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Drug Interaction Unlock Additional DataAbciximab Altrenogest may decrease the anticoagulant activities of Abciximab. Acenocoumarol Altrenogest may decrease the anticoagulant activities of Acenocoumarol. Acetylsalicylic acid Altrenogest may decrease the anticoagulant activities of Acetylsalicylic acid. Alteplase Altrenogest may decrease the anticoagulant activities of Alteplase. Ancrod Altrenogest may decrease the anticoagulant activities of Ancrod. Anistreplase Altrenogest may decrease the anticoagulant activities of Anistreplase. Antithrombin Alfa Altrenogest may decrease the anticoagulant activities of Antithrombin Alfa. Antithrombin III human Altrenogest may decrease the anticoagulant activities of Antithrombin III human. Apixaban Altrenogest may decrease the anticoagulant activities of Apixaban. Ardeparin Altrenogest may decrease the anticoagulant activities of Ardeparin. Additional Data Available- Extended DescriptionExtended DescriptionAvailable for Purchase
Extended description of the mechanism of action and particular properties of each drug interaction.
Learn more - SeveritySeverityAvailable for Purchase
A severity rating for each drug interaction, from minor to major.
Learn more - Evidence LevelEvidence LevelAvailable for Purchase
A rating for the strength of the evidence supporting each drug interaction.
Learn more - ActionActionAvailable for Purchase
An effect category for each drug interaction. Know how this interaction affects the subject drug.
Learn more
- Food Interactions
- Not Available
Categories
- Drug Categories
- Chemical TaxonomyProvided by Classyfire
- Description
- This compound belongs to the class of organic compounds known as estrogens and derivatives. These are steroids with a structure containing a 3-hydroxylated estrane.
- Kingdom
- Organic compounds
- Super Class
- Lipids and lipid-like molecules
- Class
- Steroids and steroid derivatives
- Sub Class
- Estrane steroids
- Direct Parent
- Estrogens and derivatives
- Alternative Parents
- 3-oxosteroids / 17-hydroxysteroids / Cyclohexenones / Tertiary alcohols / Cyclic alcohols and derivatives / Organic oxides / Hydrocarbon derivatives
- Substituents
- 17-hydroxysteroid / 3-oxosteroid / Alcohol / Aliphatic homopolycyclic compound / Carbonyl group / Cyclic alcohol / Cyclic ketone / Cyclohexenone / Estrogen-skeleton / Hydrocarbon derivative
- Molecular Framework
- Aliphatic homopolycyclic compounds
- External Descriptors
- Not Available
Chemical Identifiers
- UNII
- 2U0X0JA2NB
- CAS number
- 850-52-2
- InChI Key
- VWAUPFMBXBWEQY-ANULTFPQSA-N
- InChI
- InChI=1S/C21H26O2/c1-3-10-21(23)12-9-19-18-6-4-14-13-15(22)5-7-16(14)17(18)8-11-20(19,21)2/h3,8,11,13,18-19,23H,1,4-7,9-10,12H2,2H3/t18-,19+,20+,21+/m1/s1
- IUPAC Name
- (1R,3aS,3bS,11aS)-1-hydroxy-11a-methyl-1-(prop-2-en-1-yl)-1H,2H,3H,3aH,3bH,4H,5H,7H,8H,9H,11aH-cyclopenta[a]phenanthren-7-one
- SMILES
- [H][C@@]12CC[C@@](O)(CC=C)[C@@]1(C)C=CC1=C3CCC(=O)C=C3CC[C@@]21[H]
References
- General References
- Machnik M, Hegger I, Kietzmann M, Thevis M, Guddat S, Schanzer W: Pharmacokinetics of altrenogest in horses. J Vet Pharmacol Ther. 2007 Feb;30(1):86-90. [PubMed:17217407]
- Kornheiser KM: Use of altrenogest in mares. J Am Vet Med Assoc. 1989 May 1;194(9):1150. [PubMed:2722647]
- Hodgson D, Howe S, Jeffcott L, Reid S, Mellor D, Higgins A: Effect of prolonged use of altrenogest on behaviour in mares. Vet J. 2005 May;169(3):322-5. [PubMed:15912604]
- Webel SK, Squires EL: Control of the oestrous cycle in mares with altrenogest. J Reprod Fertil Suppl. 1982;32:193-8. [PubMed:6962854]
- Soede NM, Bouwman EG, Langendijk P, van der Laan I, Kanora A, Kemp B: Follicle development during luteal phase and altrenogest treatment in pigs. Reprod Domest Anim. 2007 Jun;42(3):329-32. [PubMed:17506814]
- Sigler DH, Ericson DE, Gibbs PG, Kiracofe GH, Stevenson JS: Reproductive traits, lactation and foal growth in mares fed altrenogest. J Anim Sci. 1989 May;67(5):1154-9. [PubMed:2737975]
- Stevenson JS, Davis DL, Pollmann DS: Altrenogest and fat for summer breeding of primiparous sows. J Anim Sci. 1985 Aug;61(2):480-6. [PubMed:4044446]
- dos Santos JM, Wentz I, Bortolozzo FP, Barioni W Jr: Early-weaned sows: altrenogest therapy, estrus, ovulation, and reproductive performance. Anim Reprod Sci. 2004 Sep;84(3-4):407-13. [PubMed:15302382]
- Davis DL, Stevenson JS, Schmidt WE: Scheduled breeding of gilts after estrous synchronization with altrenogest. J Anim Sci. 1985 Mar;60(3):599-602. [PubMed:3988636]
- Rhodes MT, Davis DL, Stevenson JS: Flushing and altrenogest affect litter traits in gilts. J Anim Sci. 1991 Jan;69(1):34-40. [PubMed:2005028]
- External Links
- KEGG Drug
- D02840
- ChemSpider
- 8216634
- 1314612
- ChEMBL
- CHEMBL1315492
- ZINC
- ZINC000004214784
- Wikipedia
- Altrenogest
Clinical Trials
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
- Not Available
- Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Not Available
- Experimental Properties
- Not Available
- Predicted Properties
Property Value Source Water Solubility 0.0301 mg/mL ALOGPS logP 3.74 ALOGPS logP 3.2 ChemAxon logS -4 ALOGPS pKa (Strongest Acidic) 18.4 ChemAxon pKa (Strongest Basic) -0.18 ChemAxon Physiological Charge 0 ChemAxon Hydrogen Acceptor Count 2 ChemAxon Hydrogen Donor Count 1 ChemAxon Polar Surface Area 37.3 Å2 ChemAxon Rotatable Bond Count 2 ChemAxon Refractivity 95.46 m3·mol-1 ChemAxon Polarizability 36.06 Å3 ChemAxon Number of Rings 4 ChemAxon Bioavailability 1 ChemAxon Rule of Five Yes ChemAxon Ghose Filter Yes ChemAxon Veber's Rule Yes ChemAxon MDDR-like Rule No ChemAxon - Predicted ADMET Features
- Not Available
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
Spectrum Spectrum Type Splash Key Predicted MS/MS Spectrum - 10V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 20V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 40V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 10V, Negative (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 20V, Negative (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 40V, Negative (Annotated) Predicted LC-MS/MS Not Available
Drug created on February 25, 2016 11:13 / Updated on June 12, 2020 10:53